C. Scott Garliss|
U.S. Pre-Market Stock Moves: AXL, DE, FDX, NWL, NVDA, RDFN
CymaBay Therapeutics (CBAY) +10.8%. Primary biliary cholangitis treatment receives breakthrough therapy designation from the FDA.Arista Networks (ANET) +7.4%. 1Q revenue guidance in line with expectations.SS&C Technologies (SSNC) +6.9%. 1Q revenue guidance beats expectations, boosts dividend.American Axle (AXL) +6.5%.